723 related articles for article (PubMed ID: 30777098)
1. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
3. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
4. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
5. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
6. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5.
Kamalabadi-Farahani M; H Najafabadi MR; Jabbarpour Z
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1743-1748. PubMed ID: 31244295
[TBL] [Abstract][Full Text] [Related]
8. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
9. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
[TBL] [Abstract][Full Text] [Related]
10. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death.
Li J; Sharkey CC; King MR
Sci Rep; 2015 May; 5():9987. PubMed ID: 25984950
[TBL] [Abstract][Full Text] [Related]
12. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E; Malin D; Good DM; Cryns VL
Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
[TBL] [Abstract][Full Text] [Related]
13. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
Yoon N; Park MS; Peltier GC; Lee RH
Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
[TBL] [Abstract][Full Text] [Related]
14. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.
Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I
Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724
[TBL] [Abstract][Full Text] [Related]
15. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
16. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
17. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.
Kim H; Samuel SL; Zhai G; Rana S; Taylor M; Umphrey HR; Oelschlager DK; Buchsbaum DJ; Zinn KR
Cancer Biol Ther; 2014 Aug; 15(8):1053-60. PubMed ID: 25084100
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
